Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia.

@article{Tefferi1999PhaseIS,
  title={Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia.},
  author={Ayalew Tefferi and Ralph M Levitt and Chin Li and G. Schr{\"o}der and Loren K. Tschetter and John C. Michalak and James E. Krook and Thomas E Witzig},
  journal={American journal of clinical oncology},
  year={1999},
  volume={22 5},
  pages={509-16}
}
The objective was to determine the safety and efficacy of adding a maximally tolerated dose of 2-chlorodeoxyadenosine (2-CdA) to standard chlorambucil (CLB) therapy in previously untreated B-cell chronic lymphocytic leukemia (CLL). Thirty patients with CLL (median age, 64 years) received two courses of 2-CdA given intravenously (2 mg/m2 daily for 7 days) added to biweekly administration of CLB at 30 mg/m2 given orally. The diagnosis of CLL, treatment indications, and response criteria were… CONTINUE READING